A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC)
暂无分享,去创建一个
A. Tolcher | M. Beeram | H. Burris | S. Lutzker | S. Girish | S. Modi | I. Krop | J. Tibbitts | N. Rabbee | S. Holden